Sammy Saab, MD, MPH

Key investigator

  • Sammy Saab, MD, MPH


  • Donors

Current research projects

  • Hepatic encephalopathy as a predictor of patient related outcomes after TIPS
  • Cardiovascular complications after liver transplantation
  • Prevalence of hepatitis C in the pediatric population
  • Telemedicine: Effectiveness and patient satisfaction
  • Strategies for screening for fatty liver in the community

Future research directions

  • Liver transplantation
  • Cirrhosis
  • Chronic hepatitis C

Recent publications - Full list on PubMed

  1. Saab S. Hepatic encephalopathy. Clinics in Liver Disease. May 2024.
  2. Shetty A, Saab S. Commentary on New Fatty Liver Nomenclature Steatotic Liver Disease. Clinical Gastroenterology. November 24, 2023
  3. John N, Ibrahim B, Ebaid M & Saab S. Outcomes in Patients with Liver Dysfunction Post SARS-CoV-2 Infection: What Should We Measure? Hepatic Medicine: Evidence and Research. Volume 15, 2023 issue
  4. Chow KW, Futela P, Saharan A, Saab S. Comparison on guidelines for the screening, diagnosis, and noninvasive assessment of nonalcoholic fatty liver disease. Journal of Clinical and Experimental Hepatology. September-October 2023
  5. Chow KW, Ibrahim B, Rahal K, Hsu RH, Tan T, Meneses K, Saab S. Semaglutide is effective in achieving weight loss in liver transplant recipients. Liver Transplantation. August 29, 2023
  6. Zhao M, Saab S, Craw C, Lee EW. The impact of renal function on hepatic encephalopathy following TIPS placement for refractory ascites. Biomedicines. 2 August 2023
  7. Kaldas FM, Horwitz JK, Noguchi D, Korayem I, Markovic D, Ebaid S, Agopian VG, Yersiz H, Saab S, Han SB, El Kabany M, Choi G, Shetty A, Singh J, Wray C, Barjaktarvic I, Farmer DG, Busuttil R. The evolution of redo liver transplantation over 35 years. Annals of Surgery. June 26, 2023
  8. Kugelman M, Loftus M, Owen EJ, Wadei H, Saab S. Expert perspectives for the pharmacist on facilitating and improving the use of albumin in cirrhosis. American Journal of Health-System Pharmacy. July 2023, Pages 8-6-817
  9. Shetty A, Ibrahim B, Eskander B, Saab S. Management of patients after treatment of severe alcohol-associated hepatitis. Clinical Gastroenterology. July 10, 2023
  10. Chow KW, Ebaid M, Ibrahim BM, Saab S. Epidemiology and outcomes of non-alcoholic fatty liver disease in African Americans. Clinical Liver Disease. June 22, 2023
  11. Kugelmas M, Loftus M, Owen EJ, Wadei H, Saab S. Expert perspectives for the pharmacist on facilitating and improving the use of albumin in cirrhosis. American Journal of Health-System Pharmacy. 04 April 2023 
  12. Yanny B, Alkhero M, Alani M, Stenberg D, Saharan A, Saab S. Post-COVID-19 cholangiopathy: A systematic review. J Clin Exp Hepatol. 2022 Oct 30. doi: 10.1016/j.jceh.2022.10.009
  13. Saab S, Pham N, Wu W, Dang L, Dang A, Yum J, Shim, Wu S. Spontaneous seroclearance is associated with lower liver fibrosis in treatment-naïve chronic hepatitis B patientsDigestive Diseases and Sciences. 2022 Mar 4. doi: 10.1007/s10620-022-07402-1
  14. Dawod E, Nieto J, Saab S. Endoscopic ultrasound-guided liver biopsy: Where do we stand? Am Journl Gastro. Nov 17, 2021 - Volume - Issue - 10.14309/ajg.0000000000001551
  15. Reau N, Sulkowski MS, Thomas E, Sundaram V, Xu Q, Cheng WH, Marx SE, Hayes OA, Manthena SR, Chirikov V, Dylla DE, Brooks H, Carabino JM, Saab S. Epidemiology and clinical characteristics of individuals with hepatitis C virus infection in the United States, 2017-2019Advances in Therapy. 38, 5777-5970
  16. Kullar R, Patel AP, Saab S. COVID-19 in liver transplant recipientsJ Clin Transl Hepatol. 2021 Aug 28; 9(4): 545-550
  17. Saab S, Zhao M, Asokan I, Yum JJ, Lee EW. History of hepatic encephalopathy is not a contraindication to transjugular intrahepatic portosystemic shunt placement for refractory ascitesClin Transl Gastroenterol. 2021 Aug 1; 12(8):e00378
  18. Frenette CT, Levy C, Saab S. Hepatic encephalopathy-Related hospitalization in cirrhosis: Transition of care and closing the revolving doorDig Dis Sci. 2021 June 24. doi: 10.1007/s10620-021-07075-2
  19. Flamm SL, Brown K, Wadei HM, Brown Jr RS, Kugelmas M, Samaniego-Picota M, Burra P, Poordad F, Saab S. The current management of hepatorenal syndrome-Acute kidney injury in the United States and the potential of terlipressinLiver Tranpl. 2021 Apr 13. doi: 10.1002/lt.2607

Past GI research fellows

  • Jihane N. Benhammou, MD, PhD (2019-2020)
  • Akshay Shetty, MD (2018-2019)
  • Ani Kardashian, MD (2018-2019)
  • Beshoy T. Yanny, MD (2017-2018)
  • Kelvin Nguyen, MD (2017-18)
  • Tyralee Goo, MD (2014-15)
  • Victoria Sheen, MD (2014-15)
  • Gina Choi, MD (2013-14)
  • Justin Reynolds, MD (2012-13)
  • Vivian Ng, MD (2012-13)
  • Jennifer Tan, MD (2007-09)
  • Lenna Martyak, MD (2007-08)
  • Carmen Landaverde, MD (2007-09)
  • Andrew Kim, MD (2006-07)
  • Jose Nieto, DO (2004-06)
  • Shiobhan Weston, MD (2002-03)

About Dr. Saab

Dr. Saab received his BS, MD, and MPH degrees from UCLA. He completed his residency in internal medicine at the University of California at San Diego (UCSD) Medical Center and a fellowship in gastroenterology/hepatology at the UCLA Center for Health Sciences. He also served as chief medical resident at USCD. Dr. Saab is board certified in gastroenterology and transplant hepatology.

He has received honorary fellowship from several medical societies including the American Gastroenterology Association (AGAF), the American Association for the Study of Liver Diseases (FAASLD), and the American College of Gastroenterology (ACG).

Dr. Saab is active in many local, national, and international committees. He served on the Medical Advisory Committee of the Ventura County/ West Valley Chapter of TRIO (2005-2012), Practice Guidelines Committee of the American Society of Transplantation (2006-2008), and the Educational Committee of the American Association for the Study of Liver Diseases (2004-2007). He is currently co-chair on the National Medical Advisory Committee for the American Liver Foundation. He is on the board of directors for the American Liver Foundation and Chronic Liver Disease Foundation and the Chronic Liver Disease Foundation.

Dr. Saab served on the American Association for the Study of Liver Diseases Nominating Committee in 2014. He previously served as member of United Network for Organ Sharing Membership and Professional Standards Committee and Performance Analysis and Improvement Subcommittee. Dr. Saab was also a member of the Minority Affairs Committee Member and Cultural Diversity for the American College of Gastroenterology.

Dr. Saab has been an investigator in numerous clinical trials, a frequently invited speaker worldwide, and leads an annual patient education seminar.

He has been named one of the “Best Doctors in America,” has received the Distinguished Achievement Award from his Division of Digestive Diseases. Dr. Saab has published over 300 peer-reviewed manuscripts. He has authored many book chapters, editorials, abstracts, and poster presentations. Dr. Saab is on the editorial board of more than a dozen journal, and is currently the liver section editor for the Journal of Clinical Gastroenterology.